BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma

Paola Queirolo, Francesco Spagnolo

Research output: Contribution to journalArticlepeer-review

Abstract

BRAF plus MEK-targeted drugs have out-performed BRAF inhibitor monotherapy in three randomized phase 3 studies, and such combinations have become a new standard of treatment for BRAF-mutant advanced melanoma. With an overall response rate of about 70%, no other therapy in melanoma has shown a better response rate in late-phase clinical trials than combined BRAF and MEK inhibitors; the rapid kinetics of response make them the ideal front-line treatment for symptomatic, BRAF-mutant advanced melanoma patients. Nevertheless, the development of mechanisms of resistance limits the duration of response to such treatment in the majority of cases, with only about 20% of patients treated with the combination being progression-free at 3 years. The aim of this review is to report the efficacy and safety outcomes of the combination of BRAF plus MEK inhibitors compared with BRAF inhibitor monotherapy and immunotherapy, as well as to discuss future perspectives to improve outcomes based on current clinical and translational research studies.

Original languageEnglish
Pages (from-to)35-42
Number of pages8
JournalCancer and Metastasis Reviews
Volume36
Issue number1
DOIs
Publication statusPublished - Mar 1 2017

Keywords

  • BRAF
  • Cobimetinib
  • Dabrafenib
  • MEK
  • Melanoma
  • Trametinib
  • Vemurafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma'. Together they form a unique fingerprint.

Cite this